Acetylsalicylic acid resistance in patients with type 2 diabetes mellitus, prediabetes & non-diabetic coronary artery disease

Pakistan Journal of Medical Sciences

Volumn 30, Issue 3, 2014, Pages

  Cetin, Mustafa ^a   Kiziltunc, Emrullah ^a   Cetin, Zehra Guven ^a   Cicekcioglu, Hulya ^a   Sahin, Muslum ^a   Isik, Serhat ^b   Kurtul, Alparslan ^b   Ornek, Ender ^a   Ulusoy, Feridun Vasfi ^a  

^a Department of Cardiology Ankara Education and Research Hospital ^*  (Turkey)

^b ANKARA TRAINING AND RESEARCH HOSPITAL   (Turkey)

Author keywords

Acetylsalicylic acid resistance; Coronary artery disease; Diabetes mellitus

Indexed keywords

ACETYLSALICYLIC ACID; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; INSULIN;

ADULT; ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DRUG USE; FEMALE; HUMAN; IMPAIRED GLUCOSE TOLERANCE; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; RISK ASSESSMENT; RISK FACTOR; SEX DIFFERENCE; SMOKING;

EID: 84897541482     PISSN: 1682024X     EISSN: None     Source Type: Journal    
DOI: 10.12669/pjms.303.4773     Document Type: Article

References (26)

1. Antiplatelet Trialists' Collaboration. Collaborative overview of randomized trials of antiplatelet therapy: I. Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. BMJ. 308(6921):81-106.
2. Stamler J, Vaccaro O, Neaton JD, Wentworth D. Diabetes, other risk factors, and 12-yr cardiovascular mortality for men screened in the Multiple Risk Factor Intervention Trial. Diabetes Care. 1993;16:434-444.
3. American Diabetes Association. Standards of Medical Care in Diabetes- 2013. Diabetes Care. 2013;36(Suppl 1):11-66.
4. Muir AR, McMullin MF, Patterson C, McKeown PP. Assessment of aspirin resistance varies on a temporal basis in patients with ischaemic heart disease. Heart. 2009;95:1225-1229.
5. Vejar M, Fragasso G, Hackett D, Lipkin DP, Maseri A, Born GV. Dissociation of platelet activation & spontaneous myocardial ischemia in unstable angina. Thromb Haemost. 1990;63:163-168.
6. Gum PA, Kottke-Marchant K, Welsh PA, White J, Topol EJ. A prospective, blinded determination of the natural history of aspirin resistance among stable patients with cardiovascular disease. J Am Coll Cardiol. 2003;41:961-965.
7. Mammen EF, Comp PC, Gosselin R, Greenberg C, Hoots WK, Kessler CM. PFA-100 system: a new method for assessment of platelet dysfunction. Semin Thromb Hemost. 1998;24:195-202.
8. Abaci A, Caliskan M, Bayram F, Yilmaz Y, Cetin M, Unal A. A new definition of aspirin non-responsiveness by platelet function analyzer-100 & its predictors. Platelets. 2006;17:7-13.
9. Sacco M, Pellegrini F, Roncaglioni MC, Avanzini F, Tognoni G, Nicolucci A. PPP Collaborative Group: Primary prevention of cardiovascular events with low-dose aspirin & vitamin E in type 2 diabetic patients. Diabetes Care. 2003;26:3264-3272.
10. Sobol AB, Selmaj K, Mochecka A, Kumor A, Loba J. Aspirin Responsiveness in Ischemic Stroke Patients in Relation to Diabetes Mellitus, Lipid & Hemostatic Profile. Adv Clin Exp Med. 2010;19(5):593-599.
11. Ferroni P, Basili S, Falco A, Davi G. Platelet activation in type 2 diabetes mellitus. J Thromb Haemost. 2004;2:1282-1291.
12. Ferreira IA, Mocking AI, Feijge MA, Gorter G, van Haeften TW, Heemskerk JW, et al. Platelet inhibition by insulin is absent in type 2 diabetes mellitus. Arterioscler Thromb Vasc Biol. 2006;26(2):417-422.
13. Anfossi G, Russo I, Trovati M. Platelet resistance to the anti-aggregating agents in the insulin resistant states. Curr Diabetes Rev. 2006;2:409-430.
14. Trovati M, Mularoni EM, Burzacca S, Ponziani MC, Massucco P, Mattiello L, et al. Impaired insulin-induced platelet antiaggregating effect in obesity & in obese NIDDM patients. Diabetes. 1995;44:1318-1322.
15. Watala C, Golanski J, Pluta J, Boncler M, Rozalski M, Luzak B. Reduced sensitivity of platelets from type 2 diabetic patients to acetylsalicylic acid (aspirin)-its relation to metabolic control. Thromb Res. 2004;113:101-113.
16. Pulcinelli FM, Biasucci LM, Riondino S, Giubilato S, Leo A, Di Renzo L. COX-1 sensitivity & thromboxane A2 production in type 1 & type 2 diabetic patients under chronic aspirin treatment. Eur Heart J. 2009;30:1279-1286.
17. Watala C, Pluta J, Golanski J, Rozalski M, Czyz M, Trojanowski Z. Increased protein glycation in diabetes mellitus is associated with decreased aspirin-mediated protein acetylation & reduced sensitivity of blood platelets to aspirin. J Mol Med. 2005;83:148-158.
18. Winocour PD, Watala C, Perry DW, Kinlough-Rathbone RL. Decreased platelet membrane fluidity due to glycation or acetylation of membrane proteins. Thromb Haemost. 1992;68:577-582.
19. Feher G, Koltai K, Papp E, Alkonyi B, Solyom A, Kenyeres P. Aspirin resistance: possible roles of cardiovascular risk factors, previous disease history, concomitant medications & haemorrheological variables. Drugs Aging. 2006;23:559-567.
20. Abaci A, Yilmaz Y, Caliskan M, Bayram F, Cetin M, Unal A. Effect of increasing doses of aspirin on platelet function as measured by PFA-100 in patients with diabetes. Thromb Res. 2005;116:465-470.
21. Prabhakaran S, Wells KR, Lee VH, Flaherty CA, Lopes DK. Prevalence & risk factors for aspirin and clopidogrel resistance in cerebrovascular stenting. Am J Neuroradiol. 2008;29:281-285.
22. Blanche D. Involvement of hydrogen & lipid peroxides in acute tobacco smoking-induced platelet hyperactivity. Am J Physiol. 1995;268:679-685.
23. Ichiki K, Ikeda H, Haramaki N, Ueno T, Imaizumi T. Longterm smoking impairs platelet-derived nitric oxide release. Circulation. 1996;94:3109-3114.
24. Eskandarian R, Darabian M, Heshmatnia J, Ghorbani R. Acetyl salicylic acid resistance in patients with chronicstable angina & the correlation with coronary risk factors. Saudi Med J. 2012;33(1):39-43.
25. Lee PY, Chen WH, Ng W, Cheng X, Kwok JY, Tse HF. Lowdose aspirin increases aspirin resistance in patients with coronary artery disease. Am J Med. 2005;118(7):723-727.
26. Friend M, Vucenik I, Miller M. Platelet responsiveness to aspirin in patients with hyperlipidaemia. BMJ. 2003;326:82-83.